Company Overview of GangaGen, Inc.
GangaGen, Inc. operates a biotechnology company that is focused on the discovery and development of novel therapeutics for the prevention and treatment of infectious diseases, particularly infections that are resistant to antibiotics. Its StaphTAME is a recombinant protein for the topical prevention and treatment of staplylococcal infections, including infection with methicillin-resistant Staphylococcus aureus (MRSA). The company’s StaphTAME kills bacteria in vitro and in vivo. The company was founded in 2000 and is based in Palo Alto, California. It has research and development operations in Bangalore, India.
Palo Alto, CA 94306
Founded in 2000
Key Executives for GangaGen, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact GangaGen, Inc., please visit www.gangagen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.